GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GSK Pharmaceuticals reported its FY25 audited results with standalone revenue from operations rising 9.3% YoY to Rs. 3,723 crore and net profit jumping 57% to Rs. 919 crore (vs Rs. 585 crore in FY24, which was hit by a one-time VRS charge). Q4 FY25 standalone profit grew about 35% YoY to Rs. 260 crore. The Board has recommended a final dividend of Rs. 42 per share (up from Rs. 32 last year, a 31% increase) on the face value of Rs. 10, subject to shareholder approval. The Board re-appointed Dr. Sunita Maheshwari as an Independent Director for a second term of three years and appointed Parikh & Associates as the new Secretarial Auditor for a first term of five years (FY26-FY30). The 100th AGM is fixed for 27th June 2025, with 30th May 2025 as the record date for the dividend.
Strong profit growth and a meaningful hike in dividend should be viewed positively by shareholders. Despite the headline suggesting a 'change in management,' there is no CEO/CFO/MD change — Bhushan Akshikar continues as Managing Director. The re-appointment of an existing Independent Director and the routine appointment of a Secretarial Auditor are standard corporate housekeeping items and unlikely to move the stock.